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Summary  Clinical  data  regarding  use  of  antiepileptic  drugs  in  the  elderly  are  generally  scarce.
Therefore, a  subanalysis  of  subjects  aged  ≥65  years  who  participated  in  the  3  phase  III  per-
ampanel studies  was  undertaken  to  determine  efﬁcacy  and  safety  in  these  patients.  Efﬁcacy
(change in  seizure  frequency/28  days  and  50%  responder  rate)  in  the  elderly  subgroup  was
found to  be  consistent  with  the  adult  population.  Adverse  event  rates  were  also  largely  similar,Perampanel with some  exceptions.  Because  risks  of  falls,  dizziness,  and  fatigue  were  greater  in  the  elderly,
careful titration  of  perampanel  in  patients  aged  ≥65  years  is  suggested,  especially  at  higher
doses, where  balancing  tolerability  and  clinical  response  is  necessary.
© 2014  The  Authors.  Published  by  Elsevier  B.V.  This  is  an  open  access  article  under  the  CC
BY-NC-ND  license  (http://creati
Abbreviations: AE, adverse event; AED, antiepileptic drug;
OCF, last observation carried forward; MedDRA, Medical Dictionary
or Regulatory Activities; PER, perampanel; PK, pharmacoki-
etic; SAE, serious adverse event; SD, standard deviation; TEAE,
reatment-emergent adverse event.
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erampanel,  a  selective,  orally  active,  noncompetitive  AMPA
eceptor  antagonist  (Hanada  et  al.,  2011)  has  demonstrated
fﬁcacy  and  tolerability  for  patients  with  partial  seizures
n  three  multinational  phase  III  studies  (French  et  al.,
012,  2013;  Krauss  et  al.,  2012;  Steinhoff  et  al.,  2013).
erampanel  is  approved  in  ≥40  countries  for  adjunctive
reatment  of  partial  seizures  with  or  without  secondar-
ly  generalized  seizures  in  patients  with  epilepsy,  including
he  US  and  the  EU  (ages  ≥12  years)  and  Canada  (ages
18  years)  (Fycompa  Product  Monograph  2013;  Fycompa
is an open access article under the CC BY-NC-ND license
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sEfﬁcacy  and  safety  of  perampanel  in  the  subgroup  of  elderly
Prescribing  Information  2014;  Fycompa  Summary  of  Product
Characteristics  2012).
The  elderly  are  a  rapidly  growing  segment  of  the  epilepsy
population,  and  obtaining  information  regarding  the  efﬁcacy
and  safety  of  antiepileptic  drugs  (AEDs)  in  this  popula-
tion  is  essential.  Evaluating  AEDs  in  elderly  patients  has
been  challenging,  and  these  patients  have  been  under-
represented  in  clinical  studies,  partly  due  to  intentional
exclusion  of  patients  aged  ≥65  years  in  many  studies.  Stud-
ies  that  do  include  older  patients  are  generally  small,
making  safety  and  efﬁcacy  analyses  difﬁcult  or  impossible
(Leppik  et  al.,  2006).  Moreover,  identifying  the  presence
and  types  of  seizures  in  older  patients,  and  distinguishing
them  from  other  neurological  conditions,  can  be  difﬁcult
and  can  predispose  to  misdiagnosis  (Brodie  et  al.,  2009).
Recruiting  elderly  patients  for  phase  III  studies  is  also  chal-
lenging,  since  comorbidities  (e.g.,  dementia  or  diabetes)
or  physical  frailty  may  interfere  with  trial  participation
and  affect  outcomes  (Brodie  et  al.,  2009;  Leppik  et  al.,
2006).
Population  pharmacokinetic  (PK)  analyses  have  shown
that  perampanel  clearance  is  not  meaningfully  affected  by
age.  Therefore,  we  undertook  a  subanalysis  of  the  three
phase  III  studies  in  subjects  with  partial  seizures  aged  ≥65
years  treated  with  perampanel  to  describe  its  efﬁcacy  and
safety  in  this  population.
Methods
The  three  phase  III  studies  (study  304,  NCT00699972;  study
305,  NCT00699582;  study  306,  NCT00700310)  were  multi-
national,  randomized,  double-blind,  and  placebo-controlled
(French  et  al.,  2012,  2013;  Krauss  et  al.,  2012).  Each
involved  a  6-week  pre-randomization  baseline,  19-week
double-blind  phase  (6-week  titration  and  13-week  mainte-
nance),  and  4-week  follow-up.  During  titration,  perampanel
doses  increased  weekly  (2  mg/day/week)  until  the  random-
ized  dose  or  intolerability  was  reached.  Perampanel  dosing
was  8  and  12  mg/day  in  studies  304  and  305,  and  2,  4,  and
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Table  1  Patient  baseline  characteristics:  elderly  and  adult  subgr
Elderly  subgr
(≥65  years)  
Mean  age*,  years  (SD)  68.5  (3.5)  
Females,  n  (%)  17  (60.7)  
Mean weight,  kg  (SD)  72.9  (15.9)  
Seizure type,  n  (%)
Simple  partial  without  motor  signs  7  (25.0)  
Simple partial  with  motor  signs  5  (17.9)  
Complex partial 25  (89.3)  
Partial with  secondary  generalization 15  (53.6)
AEDs at  baseline,  n  (%)
Total  28  (100.0)  
1 AED  7  (25.0)  
2 AEDs  12  (42.9)  
3 AEDs  9  (32.1)  
AED, antiepileptic drug; SD, standard deviation.
* Age at consent.ients  included  in  the  phase  III  epilepsy  clinical  trials  217
 mg/day  in  study  306.  All  studies  complied  with  the  Helsinki
eclaration,  European  Medicines  Agency  requirements,  and
he  US  Code  of  Federal  Regulations,  as  appropriate.  All
ubjects  provided  written  informed  consent  (French  et  al.,
012,  2013;  Krauss  et  al.,  2012).
Eligible  subjects,  aged  ≥12  years  and  diagnosed  with  par-
ial  seizures,  according  to  the  1981  International  League
gainst  Epilepsy  Classiﬁcation  of  Epileptic  Seizures  (ILAE,
981),  must  have  had  uncontrolled  partial  seizures,  failed
2  AEDs  in  the  previous  2  years,  had  ≥5  partial  seizures
uring  6-week  baseline,  and  been  taking  a  stable  regimen
f  1—3  AEDs  (French  et  al.,  2012,  2013;  Krauss  et  al.,  2012).
he  current  analysis  included  all  elderly  subjects  aged  ≥65
ears  in  the  pooled  study  population,  with  comparison  to
hose  aged  ≥18—<65  years.  An  additional  analysis  included
ubjects  aged  ≥60  years,  considered  an  older  population.
The  primary  efﬁcacy  endpoint  for  the  current  analysis
as  median  percent  change  in  seizure  frequency/28  days
uring  the  double-blind  period  relative  to  baseline;  the
econdary  efﬁcacy  endpoint  was  the  50%  responder  rate
percent  of  patients  achieving  ≥50%  reduction  in  seizure
requency/28  days  during  maintenance  vs  baseline,  with
he  last  observation  carried  forward  [LOCF]).  Treatment-
mergent  adverse  events  (TEAEs)  were  also  recorded  to
ssess  safety.
esults
aseline  population  characteristics
he  elderly  group  comprised  1.9%  of  the  total  pooled  phase
II  population,  with  data  being  derived  for  28  subjects  aged
65  years  vs  1307  adult  subjects  (≥18—<65  years).  Base-
ine  characteristics  were  similar  between  elderly  and  adult
ubgroups.  Complex  partial  seizures  were  the  most  common
ype  experienced  by  both  the  elderly  (89.3%)  and  adult  sub-
roups  (85.5%)  at  baseline  (Table  1).  Most  subjects  were
aking  2  concomitant  AEDs  at  baseline  (elderly:  42.9%  vs
dult:  51.3%,  Table  1).  Stroke  etiology  accounted  for  7.1%
oups.
oup
(n  =  28)
Adult  subgroup
(≥18—<65  years)  (n  =  1307)
36.3  (11.8)
683  (52.3)
71.4  (17.5)
447  (34.2)
378  (28.9)
1117  (85.5)
920  (70.4)
1307  (100.0)
173  (13.2)
671  (51.3)
463  (35.4)
218  I.E.  Leppik  et  al.
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tig.  1  Median  percent  change  from  baseline  in  seizure  freq
dult subgroups  in  three  phase  III  studies.  PER  =  perampanel.
nd  1.1%  of  the  elderly  and  adult  subgroups,  respectively.
tructural  brain  anomalies  were  the  most  common  known
tiology  for  both  subgroups  (elderly:  17.9%  vs  adult:  15.2%).
fﬁcacy
lderly  subjects  were  generally  responsive  to  perampanel
s  placebo  (Fig.  1).  Median  percent  reductions  in  seizure
requency/28  days  were  16.9%  and  12.5%  for  the  8-  and  12-
g  groups,  respectively,  vs  6.8%  for  placebo.  Sample  sizes
or  the  2-  (n  =  3)  and  4-mg  (n  =  1)  groups  were  insufﬁcient  for
eaningful  comparisons.  50%  responder  rates  were  22.2%
nd  42.9%  in  the  8-  and  12-mg  groups,  respectively,  vs  25%
or  placebo.  Efﬁcacy  endpoint  results  for  elderly  and  adult
atients  were  consistent.
(
j
s
ig.  2  Very  common* treatment-emergent  adverse  events  (TEAEs)
hree phase  III  studies.  PER  =  perampanel. * Very  common  TEAEs  (ad
fter last  dose  of  study  drug;  or  begins  before  the  ﬁrst  dose  date  an
hat occurred  in  ≥10%  of  subjects  in  any  treatment  group  in  the  enty  per  28  days  (A)  and  50%  responder  rates  (B)  for  elderly  and
afety
verall,  TEAE  incidence  rates  were  similar  between  elderly
nd  adult  subgroups  treated  with  perampanel  (85.0%  vs
7.4%,  respectively).  Very  common  TEAEs  (≥10%  in  the
ntire  population  of  the  double-blind  clinical  studies)
bserved  in  elderly  subjects  receiving  perampanel  included
izziness,  somnolence,  fatigue,  irritability,  and  fall  (Fig.  2);
izziness,  fatigue,  and  falls  occurred  somewhat  more  fre-
uently  compared  to  the  adult  subgroup.  Other  common
EAEs  observed  in  the  elderly  perampanel  group  related  to
alls  risk  (Weerdesteyn  et  al.,  2008)  were  gait  disturbance
n  = 3,  15%)  and  balance  disorder  (n  =  2,  10%).
Serious  adverse  events  (SAEs)  were  reported  in  5  sub-
ects  aged  ≥65  years.  One  placebo  subject  experienced  a
ubdural  hemorrhage,  considered  unrelated  to  study  drug.
 among  subjects  ≥65  years  of  age  and  ≥18—<65  years  of  age  in
verse  event  that  begins  on/after  ﬁrst  dose  and  up  to  30  days
d  increases  in  severity  during  the  treatment  period)  are  those
ire  epilepsy  phase  III  double-blind  pool.
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Another  subject,  receiving  8-mg  perampanel,  experienced
aortic  stenosis,  believed  to  be  unrelated  to  study  drug.
SAEs  in  elderly  patients  receiving  12-mg  perampanel  (n  =  3)
included:  subject-1,  grand  mal  convulsion  (with  fall  and
wrist  fracture)  designated  as  possibly  treatment  related;
subject-2,  head  injury,  hyponatremia  (twice),  convulsion
(with  disorientation),  none  of  which  were  categorized  as
treatment  related;  subject-3,  status  epilepticus  (with  uri-
nary  incontinence),  reported  as  possibly  treatment  related.
There  were  no  reports  of  serious  psychiatric  or  behavioral
reactions  in  elderly  subjects.  Study  subjects  recovered  from
all  reported  SAEs.
Four  (20.0%)  elderly  subjects  receiving  perampanel  dis-
continued  due  to  adverse  events  (AEs);  all  were  in  the  12-mg
group.  Two  subjects  discontinued  due  to  an  SAE  (described
above):  grand  mal  convulsion  (with  a  fall)  or  status  epilepti-
cus.  The  remaining  2  subjects  withdrew  after  experiencing
ataxia,  dizziness,  and  gait  disturbance  or  after  experiencing
a  ‘‘drunken  feeling.’’  In  all  cases,  the  subjects  recovered
from  the  event  that  caused  withdrawal.
Older  population
We  also  sought  to  determine  the  efﬁcacy  and  safety  of
perampanel  in  older  subjects,  i.e.,  ≥60  years  old  (total
n  =  65  subjects).  Median  percent  reductions  in  seizure
frequency  for  8-mg  and  12-mg  perampanel  were  36.0%
(n  =  24)  and  16.4%  (n  =  14),  respectively,  which  was  similar
to  the  ≥18—<60-year-old  subgroup  (8-mg  =  26.3%  and  12-
mg  =  27.2%)  and  numerically  higher  than  subjects  aged  ≥65
years  (8-mg  =  16.9%  and  12-mg  =  12.5%;  Fig.  1).  Although  the
responder  rate  for  the  older  population  (8-mg  =  29.2%;  12-
mg  =  28.6%)  was  similar  to  the  ≥18—<60-year-old  subgroup
(8-mg  =  35.0%;  12-mg  =  34.5%),  it  was  quite  high  in  the  older
placebo  group  (n  =  20;  35%).  Overall,  the  incidence  of  TEAEs
was  similar  between  subjects  aged  ≥60  years  and  those
≥18—<60  years  treated  with  perampanel  (86.7%  vs  77.1%,
respectively).  The  incidence  of  very  common  TEAEs  was  also
similar  in  subjects  aged  ≥60  (data  not  shown)  relative  to  the
elderly  subgroup  (≥65;  Fig.  2).
Discussion
The  physiological  status  of  the  elderly  population  often
increases  their  susceptibility  to  safety  and  tolerability  issues
with  AEDs  (Brodie  et  al.,  2009).  Age-related  conditions
including  chronic  renal  disease,  which  may  interfere  with
drug  clearance;  dementia,  affecting  treatment  adherence;
and  physical  frailty  put  elderly  patients  at  higher  risk  for
AEs,  making  them  less  likely  to  be  recruited  for  clinical  stud-
ies.  Elderly  patients  frequently  use  several  drugs  to  treat
multiple  morbidities  (polypharmacy),  increasing  their  risk
for  clinically  important  drug  interactions  (Perucca  et  al.,
2006).  In  addition,  the  efﬁcacy  of  therapies  may  be  compro-
mised  by  comorbidities  (Brodie  et  al.,  2009;  Leppik  et  al.,
2006).
In  our  analysis,  the  efﬁcacy  results  for  the  8-  and  12-
mg  doses  were  comparable  between  the  elderly  and  adult
subgroups.  The  elderly  experienced  an  elevated  risk  of  falls,
which  may  be  related  to  age-related  comorbidities.  The  sub-
jects  had  a  relatively  high  rate  of  stroke  etiology,  which  is
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tself  a  signiﬁcant  risk  for  falls  (Weerdesteyn  et  al.,  2008).
n  the  elderly  subgroup,  dizziness  and  fatigue,  in  addition
o  falls  and  related  AEs  (ataxia,  balance  disorder),  were
omewhat  more  frequent  vs  the  adult  subgroup  (≥18  to  <65
ears).  The  elevated  risk  of  selected  AEs,  particularly  falls,
nderscores  the  importance  of  a  cautious  approach  to  dose
itration,  especially  toward  higher  dose  levels,  in  elderly
atients.
Although  this  analysis  of  perampanel  is  limited  by  the
ize  of  the  elderly  subgroup  (28  patients),  the  results  are
argely  consistent  with  existing  perampanel  data.  We  were
lso  interested  in  the  efﬁcacy  and  safety  of  perampanel  in
n  older  population,  aged  ≥60  years.  The  median  percent
eduction  in  seizure  frequency  was  numerically  higher  when
atients  aged  ≥60  were  included,  and  the  incidence  of  very
ommon  TEAEs  was  similar  relative  to  the  elderly  subgroup
≥65  years).  Although  ‘‘elderly’’  is  deﬁned  by  the  WHO  as
ged  ≥65  in  developed  countries  (WHO,  2014),  studying  sub-
ects  aged  ≥60  provides  additional  context  and  support  for
erampanel  use  in  these  patients.
onclusions
his  analysis  of  patients  with  partial  seizures  aged  ≥65  years
ho  had  participated  in  perampanel  phase  III  studies  demon-
trates  similar  efﬁcacy  rates  compared  to  the  larger  adult
opulation.  The  incidence  of  most  AEs  was  not  elevated  in
lderly  patients,  but  falls,  dizziness,  fatigue,  and  balance
isorders  were  more  common.  Consequently,  it  is  advisable
hat  dosing  titration  proceed  cautiously  in  patients  aged
65  years,  especially  toward  higher  doses,  where  a  bal-
nce  between  tolerability  and  clinical  response  is  needed
Fycompa  Prescribing  Information  2014).
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